Clear Street Maintains Buy on Protagonist Therapeutics, Raises Price Target to $116

Clear Street analyst Kaveri Pohlman maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $104 to $116.